Clinical Research Directory
Browse clinical research sites, groups, and studies.
MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
Sponsor: Chong Kun Dang Pharmaceutical
Summary
The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients
Official title: A Multicenter, Randomization, Open-label Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
158
Start Date
2023-11-15
Completion Date
2025-11
Last Updated
2024-12-16
Healthy Volunteers
No
Conditions
Interventions
Myreptic-N Tablet
Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
Mycophenolate mofetil Tablet/Capsule
Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
Locations (1)
Seoul National University Hospital
Seoul, Seoul, South Korea